Biophytis (BPTSY) Stock Price, News & Analysis

Company Overview

Biophytis S.A. is a clinical-stage biotechnology company headquartered in France that develops therapeutic candidates for age-related diseases and conditions associated with muscle and respiratory decline. The company’s research focuses on small-molecule treatments intended to improve muscle function, physical performance and resilience in vulnerable patient populations.

Biophytis’ lead product candidate is Sarconeos, also known as BIO101, an orally administered small molecule derived from a plant-based compound. The candidate has been studied for sarcopenia, a progressive loss of muscle mass and strength, and for severe respiratory manifestations associated with COVID-19. Biophytis has conducted clinical development activities in Europe, the United States and Brazil.

Biophytis was founded in 2006 and is listed on Euronext Growth Paris, with American depositary shares traded in the United States under the symbol BPTSY. The company has been led by co-founder Stanislas Veillet, who has served as chairman and chief executive officer. As a clinical-stage biotechnology company, Biophytis’ programs remain subject to clinical, regulatory and commercial development risks.

Key Stats

• Today's Range: $0.25 to $0.25
• 50-Day Range: $0.25 to $0.25
• 52-Week Range: $0.00 to $2.08
• Volume: N/A
• Average Volume: 1,154 shs
• Market Capitalization: $586.50 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BPTSY
• CIK: 1768946
• Web: www.biophytis.com
• Phone: 33-1-44-27-23-00
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.41
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($16.18) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 2,346,000
• Free Float: 338,000
• Market Cap: $586.50 thousand
• Optionable: N/A
• Beta: 2.46